<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND OBJECTIVES: The translocation t(8;14)(q24;q32), involving the c-myc gene (8q24) and the immunoglobulin heavy chain (IgH) locus (14q32), represents about 75% of <z:hpo ids='HP_0000001'>all</z:hpo> chromosomal translocations in Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Due to the large variability of the breakpoint region, only the recently improved long-distance LD-polymerase chain reaction (PCR) allows the specific c-myc/IgH fusion to be identified at the genomic level </plain></SENT>
<SENT sid="2" pm="."><plain>The sensitivity of the LD-PCR is only 10(-2) to 10(-3) due to the relatively large size of the amplification products (1 to 10 kbp) </plain></SENT>
<SENT sid="3" pm="."><plain>We, therefore, established a more sensitive nested PCR with a specific primer combination for each patient based on sequence analysis of the variant breakpoint regions </plain></SENT>
<SENT sid="4" pm="."><plain>DESIGN AND METHODS: Using the combined PCR methods, we analyzed bone marrow and peripheral blood without visible blasts at diagnosis from 18 patients with t(8;14)-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: In tests employing dilutions of genomic DNA from the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell line CA-46 in the T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell line KARPAS-299, which lacks the t(8;14), the sensitivity increased 100-fold, to 10(-5) </plain></SENT>
<SENT sid="6" pm="."><plain>However, the investigation of 18 c-myc/IgH-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> patients with each breakpoint-specific nested PCR showed an inter-patient variability of sensitivity between 10(-3) and 10(-5) </plain></SENT>
<SENT sid="7" pm="."><plain>Using this assay, the rearrangement was detected in 4/16 bone marrow samples and in 6/15 peripheral blood samples without visible blasts at diagnosis </plain></SENT>
<SENT sid="8" pm="."><plain>INTERPRETATION AND CONCLUSIONS: Using the combined PCR methods the detection of c-myc/IgH reaches a level of sensitivity required for the evaluation of <z:e sem="disease" ids="C0242596" disease_type="Neoplastic Process" abbrv="MRD">minimal residual disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e>) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> patients </plain></SENT>
<SENT sid="9" pm="."><plain>Furthermore, the results highlight the importance of verifying the patient-specific sensitivity level for individual <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> monitoring </plain></SENT>
</text></document>